In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation
BioDrugs · 2026-05 · 40 (3) · 433-458
DOI: 10.1007/s40259-026-00771-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BioDrugs, online erschienen am 12.03.2026. Verfasst von Xiaoyi Dong und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Central South University, Changsha, 410…. Hauptthemen laut MEDLINE: T-Lymphocytes, Immunotherapy, Adoptive, Cell Engineering. Die Arbeit nennt 184 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Key Research and Development Plan of Hunan Province, Provincial Natural Science Foundation of Hunan.
Abstract (Originalsprache)
Adoptive cell therapies involving chimeric antigen receptor (CAR)-T cells have been demonstrated to be efficient treatments for hematologic malignancies and have successfully completed clinical translation. While traditional ex vivo T-cell engineering is still limited by challenges such as time-consuming processes, high costs, and poor controllability, as an emerging strategy, in vivo T-cell engineering involves the generation of functional effector T cells directly within patients through several injections of delivery vectors, which can reach cell therapies in days, further reducing costs and increasing scalability. This review logically outlines the technical development and application of in vivo T-cell engineering, with a particular focus on innovations in delivery systems, in which we elaborate on the mechanism and latest advances in viral vector platforms and RNA-based platforms. Furthermore, we analyzed the delivery platforms of multiple therapeutic candidates and their available data, discussing their therapeutic efficacy and safety profiles in both animal models and clinical applications. Although some challenges remain in solid tumor targeting, precise regulation, and manufacturing, increasing preclinical and clinical data have revealed the immense therapeutic potential of in vivo programming strategies across a broad spectrum of diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Central South University, Changsha, 410013, Hunan, China.
- The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University,…
- The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Central South University, Changsha, 410013, Hunan, China. 246501044@csu.edu.cn.
- The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Central South University, Changsha, 410013, Hunan, China. wuminghua554@aliyun.com.
- FuRong Laboratory, Changsha, 410078, Hunan, China. wuminghua554@aliyun.com.
- Xiangya School of Public Health, Central South University, Changsha, 410013, Hunan, China. wuminghua554@aliyun.com.
Förderung
- National Natural Science Foundation of China
- the Key Research and Development Plan of Hunan Province
- Provincial Natural Science Foundation of Hunan
- Scientific Research Program of FuRong Laboratory
- Changsha Municipal Natural Science Foundation
Zitieren
APA
Dong, X., Yan, W., Long, X., & Wu, M. (2026). In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation. BioDrugs, 40(3), 433-458. https://doi.org/10.1007/s40259-026-00771-3
Vancouver
Dong X, Yan W, Long X, Wu M. In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation. BioDrugs. 2026;40(3):433-458. doi:10.1007/s40259-026-00771-3
BibTeX
@article{Dong2026,
author = {Dong, Xiaoyi and Yan, Wei and Long, Xinmiao and Wu, Minghua},
title = {In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation},
journal = {BioDrugs},
year = {2026},
volume = {40},
number = {3},
pages = {433--458},
doi = {10.1007/s40259-026-00771-3}
}
EUVIMED